Ginzburg Yelena Z
Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Vitam Horm. 2019;110:17-45. doi: 10.1016/bs.vh.2019.01.002. Epub 2019 Feb 8.
Hepcidin is central to regulation of iron metabolism. Its effect on a cellular level involves binding ferroportin, the main iron export protein, resulting in its internalization and degradation and leading to iron sequestration within ferroportin-expressing cells. Aberrantly increased hepcidin leads to systemic iron deficiency and/or iron restricted erythropoiesis. Furthermore, insufficiently elevated hepcidin occurs in multiple diseases associated with iron overload. Abnormal iron metabolism as a consequence of hepcidin dysregulation is an underlying factor resulting in pathophysiology of multiple diseases and several agents aimed at manipulating this pathway have been designed, with some already in clinical trials. In this chapter, we present an overview of and rationale for exploring the development of hepcidin agonists and antagonists in various clinical scenarios.
铁调素是铁代谢调节的核心。它在细胞水平上的作用包括与主要的铁输出蛋白铁转运蛋白结合,导致其内化和降解,从而使铁在表达铁转运蛋白的细胞内蓄积。铁调素异常增加会导致全身性缺铁和/或铁限制的红细胞生成。此外,在多种与铁过载相关的疾病中,铁调素升高不足。铁调素失调导致的铁代谢异常是多种疾病病理生理学的潜在因素,并且已经设计了一些旨在操纵该途径的药物,其中一些已经进入临床试验阶段。在本章中,我们概述了在各种临床情况下探索铁调素激动剂和拮抗剂的开发及其原理。